Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

March 31, 2025

Conditions
Breast CancerChemotherapeutic Toxicity
Interventions
DRUG

Placebo

Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.

DRUG

Coenzyme Q10 200mg twice daily

400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.

Trial Locations (1)

22511

RECRUITING

Damanhour Oncology Center, Damanhūr

All Listed Sponsors
lead

Damanhour University

OTHER